ANI Pharmaceuticals to Discuss Second Quarter 2025 Financial Results on August 8, 2025, at 8:30 a.m. ET
ANI Pharmaceuticals (NASDAQ: ANIP) has scheduled its second quarter 2025 financial results announcement for Friday, August 8, 2025, before market open. The company will host a conference call at 8:30 a.m. ET to discuss the results.
Key executives participating in the call include CEO Nikhil Lalwani, CFO Stephen P. Carey, Head of Rare Disease Chris Mutz, and Chief Medical Officer Mary Pao, M.D., Ph.D. Investors can access the call via toll-free number 800-343-4136 using conference ID 5034065. A webcast will be available on the company's website under the Investors section.
ANI Pharmaceuticals (NASDAQ: ANIP) ha programmato l'annuncio dei risultati finanziari del secondo trimestre 2025 per venerdì 8 agosto 2025, prima dell'apertura del mercato. La società terrà una conference call alle 8:30 a.m. ET per discutere i risultati.
I principali dirigenti che parteciperanno alla chiamata includono il CEO Nikhil Lalwani, il CFO Stephen P. Carey, il Responsabile delle Malattie Rare Chris Mutz e il Chief Medical Officer Mary Pao, M.D., Ph.D. Gli investitori potranno accedere alla chiamata tramite il numero verde 800-343-4136 utilizzando l'ID conferenza 5034065. Una trasmissione in diretta sarà disponibile sul sito web della società nella sezione Investitori.
ANI Pharmaceuticals (NASDAQ: ANIP) ha programado el anuncio de sus resultados financieros del segundo trimestre de 2025 para el viernes 8 de agosto de 2025, antes de la apertura del mercado. La compañía realizará una conferencia telefónica a las 8:30 a.m. ET para comentar los resultados.
Los principales ejecutivos que participarán en la llamada incluyen al CEO Nikhil Lalwani, al CFO Stephen P. Carey, al Jefe de Enfermedades Raras Chris Mutz y a la Directora Médica Mary Pao, M.D., Ph.D. Los inversores podrán acceder a la llamada mediante el número gratuito 800-343-4136 utilizando el ID de conferencia 5034065. Habrá una transmisión web disponible en el sitio web de la compañía, en la sección de Inversores.
ANI Pharmaceuticals (NASDAQ: ANIP)는 2025년 2분기 재무 실적 발표를 2025년 8월 8일 금요일 시장 개장 전에 예정하고 있습니다. 회사는 실적 발표를 논의하기 위해 동부시간 오전 8시 30분에 컨퍼런스 콜을 진행할 예정입니다.
콜에 참여하는 주요 임원으로는 CEO Nikhil Lalwani, CFO Stephen P. Carey, 희귀질환 담당 Chris Mutz, 그리고 Chief Medical Officer Mary Pao, M.D., Ph.D가 있습니다. 투자자들은 무료 전화번호 800-343-4136와 컨퍼런스 ID 5034065를 통해 콜에 접속할 수 있습니다. 회사 웹사이트의 투자자 섹션에서 웹캐스트도 제공됩니다.
ANI Pharmaceuticals (NASDAQ : ANIP) a programmé l'annonce de ses résultats financiers du deuxième trimestre 2025 pour le vendredi 8 août 2025, avant l'ouverture des marchés. La société organisera une conférence téléphonique à 8h30 ET pour discuter des résultats.
Les principaux dirigeants participant à l'appel incluent le PDG Nikhil Lalwani, le directeur financier Stephen P. Carey, le responsable des maladies rares Chris Mutz et la directrice médicale Mary Pao, M.D., Ph.D. Les investisseurs peuvent accéder à l'appel via le numéro vert 800-343-4136 en utilisant l'identifiant de conférence 5034065. Un webcast sera disponible sur le site internet de la société, dans la section Investisseurs.
ANI Pharmaceuticals (NASDAQ: ANIP) hat die Bekanntgabe der Finanzergebnisse für das zweite Quartal 2025 für Freitag, den 8. August 2025, vor Börsenöffnung, geplant. Das Unternehmen wird um 8:30 Uhr ET eine Telefonkonferenz abhalten, um die Ergebnisse zu besprechen.
An der Telefonkonferenz nehmen wichtige Führungskräfte teil, darunter CEO Nikhil Lalwani, CFO Stephen P. Carey, Leiter der Abteilung für seltene Krankheiten Chris Mutz und Chief Medical Officer Mary Pao, M.D., Ph.D. Investoren können die Telefonkonferenz über die gebührenfreie Nummer 800-343-4136 mit der Konferenz-ID 5034065 verfolgen. Ein Webcast wird auf der Unternehmenswebsite im Bereich Investoren verfügbar sein.
- None.
- None.
PRINCETON, N.J., Aug. 01, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its second quarter 2025 financial results on Friday, August 8, 2025, prior to the market open.
Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, Chris Mutz, Head of Rare Disease, and Mary Pao, M.D., Ph.D., Chief Medical Officer, will host a conference call to discuss the results as follows:
| Date | Friday, August 8, 2025 |
| Time | 8:30 a.m. ET |
| Toll free (U.S.) | 800-343-4136 |
| Conference ID | 5034065 |
| Webcast (live and replay) | www.anipharmaceuticals.com, under the “Investors” section |
A replay of the conference call will be available within two hours of the call’s completion and will remain accessible for two weeks by dialing 800-839-6803 and entering access code 5034065.
About ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives" by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Brands business. For more information, visit www.anipharmaceuticals.com.
Investor Relations Contact:
Lisa M. Wilson, In-Site Communications, Inc.
212-452-2793
lwilson@insitecony.com
SOURCE: ANI Pharmaceuticals, Inc.
FAQ
When will ANI Pharmaceuticals (ANIP) release Q2 2025 earnings?
How can investors access ANI Pharmaceuticals' Q2 2025 earnings call?
Who will be presenting at ANI Pharmaceuticals' Q2 2025 earnings call?
How long will ANI Pharmaceuticals' Q2 2025 earnings call replay be available?
